✦ LIBER ✦

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

✍ Scribed by Cindy L. O’Bryant; Paul Haluska; Lee Rosen; Ramesh K. Ramanathan; Balaji Venugopal; Stephen Leong; Ramesh Boinpally; Amy Franke; Karsten Witt; Jeffry Evans; Chandra Belani; S. Gail Eckhardt; Suresh Ramalingam

Publisher: Springer
Year: 2011
Tongue: English
Weight: 364 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1733-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

A phase I, open-label, randomized crosso

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicols 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 303 KB